Display options
Cite
Meshkov AN, Ershova AI, Kiseleva AV, et al. The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study. J Pers Med. 2021;11(6)doi: 10.3390/jpm11060464.
Meshkov, A. N., Ershova, A. I., Kiseleva, A. V., Shalnova, S. A., Drapkina, O. M., Boytsov, S. A., & On Behalf Of The Fh-Esse-Rf Investigators. (2021). The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study. Journal of personalized medicine, 11(6), . https://doi.org/10.3390/jpm11060464
Meshkov, Alexey N, et al. "The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study." Journal of personalized medicine vol. 11,6 (2021). doi: https://doi.org/10.3390/jpm11060464
Meshkov AN, Ershova AI, Kiseleva AV, Shalnova SA, Drapkina OM, Boytsov SA, On Behalf Of The Fh-Esse-Rf Investigators. The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study. J Pers Med. 2021 May 24;11(6). doi: 10.3390/jpm11060464. PMID: 34074024; PMCID: PMC8225162.
Copy Download .nbib Format: NLM
Share it on

J Pers Med. 2021 May 24;11(6). doi: 10.3390/jpm11060464.

The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study.

Journal of personalized medicine

Alexey N Meshkov, Alexandra I Ershova, Anna V Kiseleva, Svetlana A Shalnova, Oxana M Drapkina, Sergey A Boytsov, On Behalf Of The Fh-Esse-Rf Investigators

Affiliations

  1. Federal State Institution, National Medical Research Center for Therapy and Preventive Medicine, Min-istry of Healthcare of the Russian Federation, Petroverigsky per., 10, bld. 3, 101000 Moscow, Russia.
  2. National Medical Research Center for Cardiology, 3-ya Cherepkovskaya Street, 15A, 121552 Moscow, Russia.

PMID: 34074024 PMCID: PMC8225162 DOI: 10.3390/jpm11060464

Abstract

Heterozygous familial hypercholesterolemia (HeFH) is one of the most common genetic conditions but remains substantially underdiagnosed. The aim of our study was to investigate the prevalence of HeFH in the population of 11 different regions of Russia. Individuals were selected from the Epidemiology of Cardiovascular Risk Factors and Diseases in Regions of the Russian Federation Study. All participants who had low-density lipoprotein cholesterol (LDL-C) higher than 4.9 mmol/L, or LDL-C lower than 4.9 mmol/L, but had statin therapy, were additionally examined by FH experts. FH was diagnosed using the Dutch Lipid Clinic Network criteria, incorporating genetic testing. HeFH prevalence was assessed for 18,142 participants. The prevalence of patients with definite or probable HeFH combined was 0.58% (1 in 173). A total of 16.1% of patients with definite or probable HeFH had tendon xanthomas; 36.2% had mutations in one of the three genes; 45.6% of FH patients had coronary artery disease; 63% of HeFH patients received statins; one patient received an additional PCSK9 inhibitor; no patients received ezetimibe. Only 3% of patients reached the LDL-C goal based on 2019 ESC/EAS guidelines. Underdiagnosis and undertreatment of FH in Russia underline the need for the intensification of FH detection with early and aggressive cholesterol-lowering treatment.

Keywords: APOB; LDLR; PCSK9; Russia; coronary artery disease; familial hypercholesterolemia; prevalence

References

  1. J Am Coll Cardiol. 2017 Jul 4;70(1):1-25 - PubMed
  2. Hum Mutat. 2018 Nov;39(11):1631-1640 - PubMed
  3. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1704-1714 - PubMed
  4. J Clin Endocrinol Metab. 2018 Dec 1;103(12):4491-4500 - PubMed
  5. Genet Med. 2018 Jun;20(6):591-598 - PubMed
  6. J Am Coll Cardiol. 2020 May 26;75(20):2553-2566 - PubMed
  7. Eur Heart J. 2015 Mar 1;36(9):560-5 - PubMed
  8. Eur Heart J. 2020 Jan 1;41(1):111-188 - PubMed
  9. J Am Coll Cardiol. 2016 Jun 7;67(22):2578-89 - PubMed
  10. Can J Cardiol. 2019 Jun;35(6):744-752 - PubMed
  11. Circulation. 2020 Jun 2;141(22):1742-1759 - PubMed
  12. Atherosclerosis. 2019 Nov;290:138-139 - PubMed
  13. Circulation. 1974 Mar;49(3):476-88 - PubMed
  14. J Clin Endocrinol Metab. 2012 Nov;97(11):3956-64 - PubMed
  15. Eur Heart J. 2014 Nov 7;35(42):2950-9 - PubMed
  16. Atherosclerosis. 2004 Mar;173(1):55-68 - PubMed
  17. Lancet. 1969 Dec 27;2(7635):1380-2 - PubMed
  18. Clin Chem. 2019 Oct;65(10):1258-1266 - PubMed
  19. PLoS One. 2017 Jul 18;12(7):e0181148 - PubMed
  20. Eur J Prev Cardiol. 2020 Aug 28;: - PubMed
  21. J Am Coll Cardiol. 2019 Jul 30;74(4):512-522 - PubMed
  22. J Med Genet. 2017 Apr;54(4):217-223 - PubMed

Publication Types

Grant support